Your session is about to expire
← Back to Search
Imaging
Ventripoint Echocardiography for Single Ventricle Heart
N/A
Recruiting
Led By Piers Barker, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must not have
Patients unable to understand or consent in English will be excluded.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights
No Placebo-Only Group
Summary
This trial will test a new 3D ultrasound method to better measure heart size and function in children and young adults with single-ventricle hearts. Current methods struggle with accuracy due to the unique shapes of these hearts. The new technique uses coordinates to create detailed 3D images, aiming for more precise measurements.
Who is the study for?
This trial is for children and young adults with a type of heart disease known as functional single ventricles. Participants can be any age and at any stage of surgical treatment, provided they are undergoing or have undergone a clinically ordered echocardiogram or cardiac MRI.
What is being tested?
The study is testing the effectiveness of a new 3D echocardiographic technique called Ventripoint in assessing heart size and function compared to traditional transthoracic echocardiograms or cardiac MRIs in patients with single ventricle hearts.
What are the potential side effects?
Since this trial involves non-invasive imaging techniques like echocardiograms and MRIs, there are minimal side effects expected. The most common issues might include discomfort from lying still during the procedure or mild anxiety related to medical equipment.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I understand and can consent in English.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cardiac function of the left ventricle as measured by ejection fraction
Cardiac function of the right ventricle as measured by ejection fraction
Left Ventricular Dimension as measured by end diastolic diameter
+11 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Ventripoint 3D EchocardiogramExperimental Treatment1 Intervention
Ventripoint 3D Echo performed on subject to validate technology for use in single ventricle patients.
Group II: Transthoracic Echocardiogram or Cardiac MRIActive Control1 Intervention
Non-invasive imaging of the heart to evaluate structure and function.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Single Ventricle Heart conditions include surgical interventions, medical management, and advanced imaging techniques. Surgical procedures, such as the Fontan operation, aim to optimize blood flow and reduce the workload on the single ventricle.
Medical management often involves medications to manage symptoms and prevent complications. Advanced imaging techniques, like the coordinate-based 3-dimensional echocardiographic technique, provide detailed assessments of cardiac size and function.
This is crucial for Single Ventricle Heart patients as it allows for precise monitoring and tailored treatment plans, improving outcomes and quality of life.
Find a Location
Who is running the clinical trial?
Duke UniversityLead Sponsor
2,452 Previous Clinical Trials
2,971,691 Total Patients Enrolled
Piers Barker, MDPrincipal InvestigatorDuke University
Share this study with friends
Copy Link
Messenger